Get a head STaRT in the fight against brain tumors

Tough on the tumor. Easier on you and your caregivers.

A radiation treatment specifically designed for use inside the brain, GammaTile Therapy gives patients new hope in the fight against brain tumors. It can eliminate the need for traditional repeat radiation treatments and associated hospital or clinic visits, so patients can focus on what matters most—healing.

Is GammaTile® Therapy right for you?

Find out by answering a few simple questions.

Watch this animation, which was designed for patients and caregivers to show how GammaTile Therapy works.

How it works

Your neurosurgeon places GammaTile(s) precisely where and when treatment will help the most—at the tumor site immediately after tumor removal.

Radiation is focused right where it is needed—where the tumor is most likely to recur.

GammaTile is designed to protect healthy tissue, minimizing radiation side effects, including hair loss.[1]

Radiation therapy occurs as you go about your daily life.

The Benefits Are Clear

Improved Local Tumor Control

For patients with recurrent meningiomas and recurrent brain metastases, the use of GammaTile Therapy demonstrated a significant delay in treatment site recurrence compared to their previous treatments.[2,3]

Improved Survival

GammaTile Therapy demonstrates a potential for improved overall survival when comparing the effectiveness of surgery plus GammaTile Therapy to other treatment modalities across different clinical studies in patients with recurrent glioblastoma (GBM).[4,5]

Get a head STaRT in the fight against brain tumors.

Find a GammaTile Therapy Center near you.

GammaTile Therapy: Clinical Outcomes

Improved local tumor control in patients with recurrent meningiomas and recurrent brain metastases



Potential to extend overall survival in patients with recurrent glioblastoma (GBM)


Learn about the company that developed GammaTile Therapy.


  1. Brachman D, et al. Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial. Brachytherapy 18, S35–S36 (2019).
  2. Brachman D, et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J Neurosurg 131, 1819–1828 (2019).
  3. Nakaji P, et al. Resection and Surgically Targeted Radiation Therapy for the Treatment of Larger Recurrent or Newly Diagnosed Brain Metastasis: Results From a Prospective Trial. Cureus 12, e11570 (2020).
  4. Smith K, et al. Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial. Neuro-oncology 24, S4–S15 (2022).
  5. Tsien C, et al. Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and RT plan quality report. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):578.
  6. Odia Y, et al. Surgically targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review. Neuro-oncology 24, S16–S24 (2022).
  7. Gessler D, et al. GammaTile® brachytherapy in the treatment of recurrent glioblastomas. Neuro-oncology Adv 4, vdab185 (2021).
  8. Imber B et al. Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. J Neuro-oncol 159, 609–618 (2022).